Inflammatory Bowel Disease Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Inflammatory Bowel Disease Treatment Market
The Inflammatory Bowel Disease Treatment market size was valued at USD 26.55 billion in 2023, and the market is now projected to grow from USD 29.57 billion in 2024 to USD 44.08 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period of 2024-2032.
The Covid period was proven to be bane for this particular market. The product demand was lowered by lockdown limitations and affected the inflammatory bowel disease treatment market growth. The major factor causing havoc for this product was the strict transportation regulations that were imposed faced by this partcular market also the closure of the diagnostic centres. This particular market is still experiencing rapid growth post-pandemic period.
There are few major factors driving the growth of this particular market amongst which some are contributing to the maximum namely, the drastically rising numer of ulcerative colitis and Crohn's disease. This is the major factor influencing the inflammatory bowel disease treatment market share. Another major factor attributing the growth of this particular market is the global level awareness of these diseases.
A certain type of trend has recorded to attribute to the rapid growth of the market which is the technological advancements in the market which has been a boon for the medical professionals as it helps with efficient and effective treatment for the patients. These advancdements in the new-age edge-cutting technology has made it quite easy for the doctors to treat patient without causing any discomfort to the patients.
Comprehensive Analysis of Inflammatory Bowel Disease Treatment Market
The market is basically divided into Crohn's disease and ulcerative colitis categories on the basis of diseases. Oral and injectables make up the two segments of the worldwide market by mode of administration. Hospital pharmacies, retail pharmacies, and other make up the market's distribution channel segments.
North America is subjected to hold a large number of this particular market share and is accounted to be the leading region in this market, the reason being the risen bowel illnesses and favorable reimbursement policies for treatment of Crohn's disease and ulcerative colitis.
A few renowned and fierce corporations control a significant part of the industry, indicating market consolidation. Bristol-Myers Squibb Company (U.S.), UCB S.A. (Belgium), Bausch Health Companies Inc. (Canada), Takeda Pharmaceutical Company Limited (Tokyo), and AbbVie Inc. (U.S.) are a few of the leading industry participants.
In February 2024, A grant from the European Commission (EC) allowed Pfizer Inc. to market VELSIPITY (etrasimod) within the EU.
Segmentation Table
Attribute Details
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 5.8% from 2024 to 2032
Unit Value (USD billion)
Segmentation By Disease Indication
Ulcerative Colitis
Crohn's Disease
By Route of Administration
Oral
Injectables
By Drug Class
IL Inhibitors
TNF Inhibitors
Anti-integrin
JAK Inhibitors
Corticosteroids
ASA Drugs
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy & Other
By Geography
North America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
- U.S. (By Disease Indication)
- Canada (By Disease Indication)
Europe (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
- U.K. (By Disease Indication)
- Germany (By Disease Indication)
- France (By Disease Indication)
- Italy (By Disease Indication)
- Spain (By Disease Indication)
- Scandinavia (By Disease Indication)
- Rest of Europe (By Disease Indication)
Asia Pacific (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
- China (By Disease Indication)
- Japan (By Disease Indication)
- India (By Disease Indication)
- Australia (By Disease Indication)
- Southeast Asia (By Disease Indication)
- Rest of Asia Pacific (By Disease Indication)
Latin America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
- Brazil (By Disease Indication)
- Mexico (By Disease Indication)
- Rest of Latin America (By Disease Indication)
Middle East & Africa (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
- GCC (By Disease Indication)
- South Africa (By Disease Indication)
- Rest of MEA (By Disease Indication)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Crohn’s Disease, By Key Regions/Countries, 2023
- 4.2. Prevalence of Ulcerative Colitis, By Key Regions/Countries, 2023
- 4.3. Average Length of Therapy for Inflammatory Bowel Disease
- 4.4. Statistical Overview of Patients Undergoing Different Therapies
- 4.5. Pricing and Margin Analysis
- 4.6. New Product Launches, By Key Players
- 4.7. Key Industry Developments – Mergers, Acquisitions, and Partnerships
- 4.8. Pipeline Analysis, By Key Players
- 4.9. COVID-19 Impact on the Market
- 5. Global Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Disease Indication
- 5.1.1. Ulcerative Colitis
- 5.1.2. Crohn’s Disease
- 5.2. Market Analysis, Insights and Forecast – By Route of Administration
- 5.2.1. Oral
- 5.2.2. Injectables
- 5.3. Market Analysis, Insights and Forecast – By Drug Class
- 5.3.1. IL Inhibitors
- 5.3.2. TNF Inhibitors
- 5.3.3. Anti-integrin
- 5.3.4. JAK Inhibitors
- 5.3.5. Corticosteroids
- 5.3.6. ASA Drugs
- 5.3.7. Others
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy & Others
- 5.5. Market Analysis, Insights and Forecast – By Geography
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Disease Indication
- 6.1.1. Ulcerative Colitis
- 6.1.2. Crohn’s Disease
- 6.2. Market Analysis, Insights and Forecast – By Route of Administration
- 6.2.1. Oral
- 6.2.2. Injectables
- 6.3. Market Analysis, Insights and Forecast – By Drug Class
- 6.3.1. IL Inhibitors
- 6.3.2. TNF Inhibitors
- 6.3.3. Anti-integrin
- 6.3.4. JAK Inhibitors
- 6.3.5. Corticosteroids
- 6.3.6. ASA Drugs
- 6.3.7. Others
- 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy & Others
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.1.1. By Disease Indication
- 6.5.2. Canada
- 6.5.2.1. By Disease Indication
- 7. Europe Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Disease Indication
- 7.1.1. Ulcerative Colitis
- 7.1.2. Crohn’s Disease
- 7.2. Market Analysis, Insights and Forecast – By Route of Administration
- 7.2.1. Oral
- 7.2.2. Injectables
- 7.3. Market Analysis, Insights and Forecast – By Drug Class
- 7.3.1. IL Inhibitors
- 7.3.2. TNF Inhibitors
- 7.3.3. Anti-integrin
- 7.3.4. JAK Inhibitors
- 7.3.5. Corticosteroids
- 7.3.6. ASA Drugs
- 7.3.7. Others
- 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy & Others
- 7.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.5.1. U.K.
- 7.5.1.1. By Disease Indication
- 7.5.2. Germany
- 7.5.2.1. By Disease Indication
- 7.5.3. France
- 7.5.3.1. By Disease Indication
- 7.5.4. Spain
- 7.5.4.1. By Disease Indication
- 7.5.5. Italy
- 7.5.5.1. By Disease Indication
- 7.5.6. Scandinavia
- 7.5.6.1. By Disease Indication
- 7.5.7. Rest of Europe
- 7.5.7.1. By Disease Indication
- 8. Asia Pacific Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Disease Indication
- 8.1.1. Ulcerative Colitis
- 8.1.2. Crohn’s Disease
- 8.2. Market Analysis, Insights and Forecast – By Route of Administration
- 8.2.1. Oral
- 8.2.2. Injectables
- 8.3. Market Analysis, Insights and Forecast – By Drug Class
- 8.3.1. IL Inhibitors
- 8.3.2. TNF Inhibitors
- 8.3.3. Anti-integrin
- 8.3.4. JAK Inhibitors
- 8.3.5. Corticosteroids
- 8.3.6. ASA Drugs
- 8.3.7. Others
- 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy & Others
- 8.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.5.1. Japan
- 8.5.1.1. By Disease Indication
- 8.5.2. China
- 8.5.2.1. By Disease Indication
- 8.5.3. India
- 8.5.3.1. By Disease Indication
- 8.5.4. Australia
- 8.5.4.1. By Disease Indication
- 8.5.5. Southeast Asia
- 8.5.5.1. By Disease Indication
- 8.5.6. Rest of Asia Pacific
- 8.5.6.1. By Disease Indication
- 9. Latin America Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Disease Indication
- 9.1.1. Ulcerative Colitis
- 9.1.2. Crohn’s Disease
- 9.2. Market Analysis, Insights and Forecast – By Route of Administration
- 9.2.1. Oral
- 9.2.2. Injectables
- 9.3. Market Analysis, Insights and Forecast – By Drug Class
- 9.3.1. IL Inhibitors
- 9.3.2. TNF Inhibitors
- 9.3.3. Anti-integrin
- 9.3.4. JAK Inhibitors
- 9.3.5. Corticosteroids
- 9.3.6. ASA Drugs
- 9.3.7. Others
- 9.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy & Others
- 9.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.5.1. Brazil
- 9.5.1.1. By Disease Indication
- 9.5.2. Mexico
- 9.5.2.1. By Disease Indication
- 9.5.3. Rest of Latin America
- 9.5.3.1. By Disease Indication
- 10. Middle East & Africa Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Disease Indication
- 10.1.1. Ulcerative Colitis
- 10.1.2. Crohn’s Disease
- 10.2. Market Analysis, Insights and Forecast – By Route of Administration
- 10.2.1. Oral
- 10.2.2. Injectables
- 10.3. Market Analysis, Insights and Forecast – By Drug Class
- 10.3.1. IL Inhibitors
- 10.3.2. TNF Inhibitors
- 10.3.3. Anti-integrin
- 10.3.4. JAK Inhibitors
- 10.3.5. Corticosteroids
- 10.3.6. ASA Drugs
- 10.3.7. Others
- 10.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.4.1. Hospital Pharmacy
- 10.4.2. Retail Pharmacy & Others
- 10.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.5.1. GCC Countries
- 10.5.1.1. By Disease Indication
- 10.5.2. South Africa
- 10.5.2.1. By Disease Indication
- 10.5.3. Rest of Middle East & Africa
- 10.5.3.1. By Disease Indication
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2023)
- 11.2. Company Profiles
- 11.2.1. Pfizer Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Product
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. CELLTRION INC.
- 11.2.2.1. Overview
- 11.2.2.2. Product
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Johnson & Johnson Services, Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Product
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. AbbVie Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Product
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Takeda Pharmaceutical Company Limited
- 11.2.5.1. Overview
- 11.2.5.2. Product
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. UCB S.A.
- 11.2.6.1. Overview
- 11.2.6.2. Product
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Bausch Health Companies Inc.
- 11.2.7.1. Overview
- 11.2.7.2. Product
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Bristol-Myers Squibb Company
- 11.2.8.1. Overview
- 11.2.8.2. Product
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Eli Lilly and Company
- 11.2.9.1. Overview
- 11.2.9.2. Product
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Gilead Sciences
- 11.2.10.1. Overview
- 11.2.10.2. Product
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.11. EA Pharma Co., Ltd
- 11.2.11.1. Overview
- 11.2.11.2. Product
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Strategies
- 11.2.11.6. Financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook